Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Aug 2018
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Methotrexate
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms ELAN-UNFIT
- 09 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Aug 2018 Planned End Date changed from 1 Jun 2019 to 1 Aug 2023.
- 09 Aug 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2018.